Physician profile
Mazen Elyan
NPI 1104978048
$3,831.83
in general payments reported to CMS, 2019-2025
23 companies · $524 in 2025
The $524 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $373 · 2020: $161 · 2021: $458 · 2022: $422 · 2023: $1,760 · 2024: $134 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,855 · Food and Beverage: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,855.00 |
| Food and Beverage | $562.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $1,415.23 | 2023 | Idacio |
| Abbvie INC. | $581.11 | 2019-2025 | |
| Amgen INC. | $431.29 | 2019-2025 | Prolia, Otezla, Tavneos |
| Glaxosmithkline, LLC. | $225.09 | 2021-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $177.35 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.22 | 2019-2022 | |
| Janssen Biotech, INC. | $109.09 | 2020-2022 | |
| Cardinal Health 110 LLC | $100.00 | 2025 | |
| Ucb, INC. | $84.23 | 2019-2022 | |
| Horizon Therapeutics Plc | $83.63 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $79.87 | 2019-2024 | Orencia |
| Pfizer INC. | $74.00 | 2019-2024 | |
| Mallinckrodt Hospital Products INC. | $67.10 | 2022 | |
| Lilly USA, LLC | $66.79 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $37.63 | 2022-2023 | Saphnelo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $27.43 | 2019-2021 | |
| Genzyme Corporation | $25.51 | 2025 | |
| Ani Pharmaceuticals, INC. | $23.98 | 2023 | Purified Cortrophin Gel |
| Ferring Pharmaceuticals INC. | $19.65 | 2020 | |
| Octapharma USA, INC. | $16.10 | 2025 | Octagam Immune Globulin (Human) |
| Alexion Pharmaceuticals, INC. | $16.07 | 2021 | |
| Sandoz INC. | $15.85 | 2025 | Jubbonti |
| Actelion Pharmaceuticals US, INC. | $15.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazen Elyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.